CDNA vs GRAL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 14, 2026

CDNA

27.6
AI Score
VS
GRAL Wins

GRAL

54.7
AI Score

Investment Advisor Scores

CDNA

28score
Recommendation
SELL

GRAL

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CDNA GRAL Winner
Revenue 85.47M 249.65M CDNA
Net Income -203.43M 113.44M CDNA
Net Margin -238.0% 45.4% CDNA
Operating Income -309.55M 114.42M CDNA
ROE -8.0% 26.7% CDNA
ROA -7.2% 21.3% CDNA
Total Assets 2.84B 532.99M GRAL
Cash 55.65M 373.64M CDNA
Current Ratio 10.95 4.58 GRAL
Free Cash Flow -168.65M 29.26M CDNA

Relative Price Performance (Last 90 Days)

CDNA 1M: +29.2% · 3M: +125.4% GRAL 1M: +13.0% · 3M: +17.2%

Current Technical Phase

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (34.1% over 20 days), RSI 72

RSI (14): 71.8 · Price: $48.61

GRAL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.9% over 20 days), RSI 62

RSI (14): 61.9 · Price: $79.54

Fundamentals Snapshot

Metric CDNA GRAL
Market Cap
Forward P/E 35.9 -8.1
Trailing P/E 22.4
Revenue (TTM)
Revenue Growth 0.5% 0.3%
Gross Margin 0.7% 0.5%
Operating Margin 0.0% -3.3%
EPS 2.10 -10.21
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, GRAL is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.